The percentage of Th17/CD4+ cells in patients with newly diagnosed MM was significantly higher than that in HCs (P = 0.0037), and after chemotherapy, a gradual downward trend was observed, and cells returned to approximately normal levels in the remission group (Figure 4C). The gene discussed is CD4; the disease is Miyoshi myopathy.